Prevention of Meningococcal Disease — Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
Citation(s)
A Phase II, Randomized, Open Label, Controlled, Multicenter Study to Evaluate the Safety, Immunogenicity and Induction of Immunological Memory After Two or Three Doses of Novartis (Formerly Chiron) Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants at 2, 3, 4 or 2, 4, 6 Months of Age